Literature DB >> 23353097

Transport of organic cationic drugs: effect of ion-pair formation with bile salts on the biliary excretion and pharmacokinetics.

I S Song1, M K Choi, W S Shim, C K Shim.   

Abstract

More than 40% of clinically used drugs are organic cations (OCs), which are positively charged at a physiologic pH, and recent reports have established that these drugs are substrates of membrane transporters. The transport of OCs via membrane transporters may play important roles in gastrointestinal absorption, distribution to target sites, and biliary and/or renal elimination of various OC drugs. Almost 40 years ago, a molecular weight (Mw) threshold of 200 was reported to exist in rats for monoquaternary ammonium (mono QA) compounds to be substantially (e.g., >10% of iv dose) excreted to bile. It is well known that some OCs interact with appropriate endogenous organic anions in the body (e.g., bile salts) to form lipophilic ion-pair complexes. The ion-pair formation may influence the affinity or binding of OCs to membrane transporters that are relevant to biliary excretion. In that sense, the association of the ion-pair formation with the existence of the Mw threshold appears to be worthy of examination. It assumes the ion-pair formation of high Mw mono QA compounds (i.e., >200) in the presence of bile salts in the liver, followed by accelerated transport of the ion-pair complexes via relevant bile canalicular transporter(s). In this article, therefore, the transport of OC drugs will be reviewed with a special focus on the ion-pair formation hypothesis. Such information will deepen the understanding of the pharmacokinetics of OC drugs as well as the physiological roles of endogenous bile salts in the detoxification or phase II metabolism of high Mw QA drugs.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23353097     DOI: 10.1016/j.pharmthera.2013.01.006

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  6 in total

1.  Targeted live-cell nuclear delivery of the DNA 'light-switching' Ru(II) complex via ion-pairing with chlorophenolate counter-anions: the critical role of binding stability and lipophilicity of the ion-pairing complexes.

Authors:  Xi-Juan Chao; Miao Tang; Rong Huang; Chun-Hua Huang; Jie Shao; Zhu-Ying Yan; Ben-Zhan Zhu
Journal:  Nucleic Acids Res       Date:  2019-11-18       Impact factor: 16.971

2.  Delivering the cell-impermeable DNA 'light-switching' Ru(ii) complexes preferentially into live-cell nucleus via an unprecedented ion-pairing method.

Authors:  Ben-Zhan Zhu; Xi-Juan Chao; Chun-Hua Huang; Yan Li
Journal:  Chem Sci       Date:  2016-04-05       Impact factor: 9.825

3.  Altered toxicological endpoints in humans from common quaternary ammonium compound disinfectant exposure.

Authors:  Terry C Hrubec; Ryan P Seguin; Libin Xu; Gino A Cortopassi; Sandipan Datta; Alexandra L Hanlon; Alicia J Lozano; Valerie A McDonald; Claire A Healy; Tyler C Anderson; Najaha A Musse; Richard T Williams
Journal:  Toxicol Rep       Date:  2021-03-09

4.  Blockade of P-Glycoprotein Decreased the Disposition of Phenformin and Increased Plasma Lactate Level.

Authors:  Min-Koo Choi; Im-Sook Song
Journal:  Biomol Ther (Seoul)       Date:  2016-03-01       Impact factor: 4.634

5.  Pharmacokinetics of Jaspine B and Enhancement of Intestinal Absorption of Jaspine B in the Presence of Bile Acid in Rats.

Authors:  Min-Koo Choi; Jihoon Lee; So Jeong Nam; Yun Ju Kang; Youjin Han; Kwangik Choi; Young A Choi; Mihwa Kwon; Dongjoo Lee; Im-Sook Song
Journal:  Mar Drugs       Date:  2017-09-01       Impact factor: 5.118

6.  Ursodeoxycholate Restores Biliary Excretion of Methotrexate in Rats with Ethinyl Estradiol Induced-Cholestasis by Restoring Canalicular Mrp2 Expression.

Authors:  Min Ju Kim; Yun Ju Kang; Mihwa Kwon; Young A Choi; Min-Koo Choi; Hye-Young Chi; Hye Hyun Yoo; Chang-Koo Shim; Im-Sook Song
Journal:  Int J Mol Sci       Date:  2018-04-09       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.